J.-F. Wang, Y.-Q. Gong, Y.-H. He, W.-W. Ying, X.-S. Li, X.-F. Zhou, L.-Q. Zhou

Department of Urology, Peking University First Hospital, Beijing, China

Correction to: Eur Rev Med Pharmacol Sci 2020; 24 (12): 6605-6615–DOI: 10.26355/eurrev_202006_21646-published online on June 25, 2020.

After publication, the authors have applied some corrections to the galley proof:

–       In Table II, data display in MMP14 expression between Low and high group was inverted. This correction does not involve any statistical data modification and does not affect the conclusion of the article.

The correct table display should be as follows:

–       In Figure 4F, the cell invasion image of siRNA-2 group in T24 was misplaced. The authors have adjusted the brightness and contrast appropriately as well.

The correct Figure 4F display should be as follows:

There are amendments to this paper. The Publisher apologizes for any inconvenience this may cause.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

J.-F. Wang, Y.-Q. Gong, Y.-H. He, W.-W. Ying, X.-S. Li, X.-F. Zhou, L.-Q. Zhou
Author Correction: High expression of MMP14 is associated with progression and poor short-term prognosis in muscle-invasive bladder cancer

Eur Rev Med Pharmacol Sci
Year: 2024
Vol. 28 - N. 5
Pages: 1640-1640
DOI: 10.26355/eurrev_202403_35574